Table 1 Demographic characteristics of cases (PCR-positive for SARS-CoV-2 Delta variant) and controls (PCR-negative) in the ≥14-d-after-first-dose analysis of vaccine effectiveness of sample A (BNT162b2), B (mRNA-1273) and C (BNT162b2 or mRNA-1273)
From: BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
Study type | A Effectiveness of BNT162b2 vaccine | B Effectiveness of mRNA-1273 vaccine | C Effectiveness of BNT162b2 or mRNA-1273 vaccines | |||
|---|---|---|---|---|---|---|
Characteristics | Casesa (PCR-positive for Delta variant) | Controlsa (PCR-negative) | Casesa (PCR-positive for Delta variant) | Controlsa (PCR-negative) | Casesa (PCR-positive for Delta variant) | Controlsa (PCR-negative) |
n = 2,783 | n = 11,201 | n = 2,781 | n = 11,287 | n = 2,934 | n = 11,974 | |
Median age (IQR) years | 27 (11–35) | 26 (10–34) | 27 (12–35) | 27 (10–35) | 27 (12–36) | 27 (11–35) |
Age group no. (%) | ||||||
0–19 years | 935 (33.6) | 3,844 (34.3) | 913 (32.8) | 3,771 (33.4) | 940 (32.0) | 3,879 (32.4) |
20–29 years | 683 (24.5) | 2,888 (25.8) | 685 (24.6) | 2,877 (25.5) | 726 (24.7) | 3,073 (25.7) |
30–39 years | 755 (27.1) | 3,046 (27.2) | 757 (27.2) | 3,099 (27.5) | 811 (27.6) | 3,356 (28.0) |
40–49 years | 323 (11.6) | 1,161 (10.4) | 342 (12.3) | 1,277 (11.3) | 361 (12.3) | 1,370 (11.4) |
50–59 years | 66 (2.4) | 213 (1.9) | 65 (2.3) | 219 (1.9) | 72 (2.5) | 239 (2.0) |
60–69 years | 11 (0.4) | 26 (0.2) | 12 (0.4) | 29 (0.3) | 14 (0.5) | 34 (0.3) |
70+ years | 10 (0.4) | 23 (0.2) | 7 (0.3) | 15 (0.1) | 10 (0.3) | 23 (0.2) |
Sex | ||||||
Male | 1,810 (65.0) | 7,832 (69.9) | 1,820 (65.4) | 7,941 (70.4) | 1,899 (64.7) | 8,273 (69.1) |
Female | 973 (35.0) | 3,369 (30.1) | 961 (34.6) | 3,346 (29.6) | 1,035 (35.3) | 3,701 (30.9) |
Nationalityb | ||||||
Bangladeshi | 207 (7.4) | 954 (8.5) | 224 (8.1) | 1,022 (9.1) | 242 (8.3) | 1,107 (9.3) |
Egyptian | 76 (2.7) | 316 (2.8) | 79 (2.8) | 315 (2.8) | 84 (2.9) | 343 (2.9) |
Filipino | 240 (8.6) | 720 (6.4) | 245 (8.8) | 821 (7.3) | 263 (9.0) | 917 (7.7) |
Indian | 495 (17.8) | 2,342 (20.9) | 504 (18.1) | 2,399 (21.3) | 527 (18.0) | 2,517 (21.0) |
Nepalese | 206 (7.4) | 997 (8.9) | 208 (7.5) | 1,017 (9.0) | 212 (7.2) | 1,032 (8.6) |
Pakistani | 244 (8.8) | 1,069 (9.5) | 249 (9.0) | 1,086 (9.6) | 256 (8.7) | 1,121 (9.4) |
Qatari | 749 (26.9) | 3,090 (27.6) | 709 (25.5) | 2,904 (25.7) | 752 (25.6) | 3,117 (26.0) |
Sri Lankan | 44 (1.6) | 168 (1.5) | 45 (1.6) | 181 (1.6) | 50 (1.7) | 193 (1.6) |
Sudanese | 44 (1.6) | 143 (1.3) | 43 (1.6) | 137 (1.2) | 46 (1.6) | 148 (1.2) |
Other nationalitiesc | 478 (17.2) | 1,402 (12.5) | 475 (17.1) | 1,405 (12.5) | 502 (17.1) | 1,479 (12.4) |
Reason for PCR testing | ||||||
Clinical suspicion | 1,277 (45.9) | 5,061 (45.2) | 1,278 (46.0) | 5,150 (45.6) | 1,370 (46.7) | 5,588 (46.7) |
Contact tracing | 468 (16.8) | 1,667 (14.9) | 464 (16.7) | 1,655 (14.7) | 489 (16.7) | 1,763 (14.7) |
Survey | 468 (16.8) | 1,984 (17.7) | 474 (17.0) | 2,019 (17.9) | 491 (6.7) | 2,075 (17.3) |
Individual request | 449 (16.1) | 2,083 (18.6) | 449 (16.2) | 2,080 (18.4) | 456 (15.5) | 2,115 (17.7) |
Healthcare routine testing | 97 (3.5) | 372 (3.3) | 96 (3.5) | 356 (3.2) | 103 (3.5) | 396 (3.3) |
Other | 24 (0.9) | 34 (0.3) | 20 (0.7) | 27 (0.2) | 25 (0.9) | 37 (0.3) |
